Table 2. Comparison of the epidemiology and disease severity between the breakthrough and unvaccinated cases.
Variables | Breakthrough cases (n = 869) | Unvaccinated cases (n = 139) | P value | OR (95% CI) | |||
---|---|---|---|---|---|---|---|
Clinical symptoms, No. (%)a | |||||||
Rash | 865 (99.5) | 139 (100.0) | - | - | |||
Affected part of rash onset | |||||||
Face and neck | 333 (38.5) | 56 (40.3) | |||||
Body | 468 (54.1) | 60 (43.2) | |||||
Arms and legs | 64 (7.4) | 23 (16.5) | |||||
Fever | 294 (33.8) | 51 (36.7) | 0.510 | 0.888 (0.602–1.309) | |||
Headache | 63 (7.3) | 14 (10.1) | 0.245 | 0.975 (0.517–1.838) | |||
Arthralgiab | 10 (1.2) | 0 (0.0) | - | - | |||
Severity, No. (%) | |||||||
Mild (< 50) | 742 (85.4) | 104 (74.8) | 0.002 | 0.570 (0.365–0.890) | |||
Moderate to severe (≥ 50) | 127 (14.6) | 35 (25.8) | - | - | |||
Moderate (50–249) | 114 (89.8) | 32 (91.4) | |||||
Severe (≥ 250) | 13 (10.2) | 3 (8.6) |
OR = odds ratio, CI = confidence interval.
aEvery clinical symptom was detected and recorded; bContinuity-adjusted χ2 test was used because one of the cell frequencies was equal to zero.